Clinical Trials Directory

Trials / Completed

CompletedNCT00037518

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
46 (planned)
Sponsor
Amgen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.

Conditions

Interventions

TypeNameDescription
DRUGAMG 073

Timeline

Start date
2001-04-01
First posted
2002-05-20
Last updated
2013-05-08

Source: ClinicalTrials.gov record NCT00037518. Inclusion in this directory is not an endorsement.

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer (NCT00037518) · Clinical Trials Directory